Evidence map›Paper›PMID 41061024›Full record

ArticlePloS one2025

Inspection confirmed mold damage in schools and new use of drugs for airway obstruction: A cohort study.

Juha Pekkanen, Martin Täubel, Lauri Lehtimäki, Tero Marttila, Anne M Karvonen

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juha PekkanenDepartment of Public Health, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-1083-8777
Martin TäubelDepartment of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland.ORCID https://orcid.org/0000-0001-8082-1041
Lauri LehtimäkiAllergy Centre, Tampere University Hospital, Tampere, Finland.
Tero MarttilaFaculty of Built Environment, Tampere University, Tampere, Finland.
Anne M KarvonenDepartment of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland.ORCID https://orcid.org/0000-0003-2257-2934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo test if extent and severity of mold damage in school buildings increases the risk of new use of drugs for airway obstruction among students with a dose-response.

methodsExtent of mold damage in 110 Finnish primary and secondary school buildings in 2004 was estimated based on all technical inspections done by 2021. New asthma (n = 1,035) and use of drugs for obstructive airway diseases (n = 3,162) among 30,418 students by 2019 was defined based on drug purchases. Multilevel Cox models were adjusted for confounders obtained from Medical Birth Register.

resultsExtensive mold damage was common. Nine buildings had no or small mold damage, 19 buildings limited, 44 wide and 38 very wide damage in 2004. No association with onset of asthma was observed neither in all students nor in students with previous obstructive airway problems. Among primary school students, there was some suggestion for an association with new use of drugs for obstructive airway diseases, but with highest risk in buildings with limited damage.

conclusionsThe results from this unique and large follow-up study suggest that assessment of the extent and severity of mold damage inside building structures in Finnish schools do not identify buildings, in which students are at increased risk of developing asthma.

Indexed as

Air Pollution, IndoorAirway ObstructionAsthmaFungiSchoolsAdolescentChildCohort StudiesFemaleFinlandHumansMaleStudents

Identifiers

PMID41061024
PMCPMC12507237

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.